Open Journal Systems

Evaluation of Adverse Reactions and Clinical Rational Use of Anti-tumor Paclitaxel

Tianliang Zhao (The People's Hospital of Zhangye City,Zhangye City,Gansu Province,China)
Weinian Kang (The People's Hospital of Zhangye City,Zhangye City,Gansu Province,China)

Abstract


Objective. To study adverse reactions and clinical rational use of paclitaxel. Methods. Review and analyzed clinical data of 50 cases cancer patients treated in our hospital from January 2017 to December 2018. All cases were treated with paclitaxel only or in combination with other drugs. Monitor incidence of adverse reactions after treatment and analyze value of rational drug use. Results. Among 50 cases treated with paclitaxel, 47 (94.00%) had myelosuppression, 44 (88.00%) had alopecia, 32 (64.00%) had gastrointestinal reaction, 27 (54.00%) had hand and foot numbness, 18 (36.00%) had edema, 16 (32.00%) had liver toxicity, 15 (30.00%) had neurotoxicity, 7 (14.00%) had allergic reaction, and 5 (10.00%) had joint and muscle pain, 5 (10.00%) cases of blood system, 3 (6.00%) cases of renal toxicity, 2 (4.00%) cases of cardiac toxicity, 2 (4.00%) cases of fever and other adverse reactions. Conclusion. Paclitaxel is common anti-tumor drug, but its safety is not high. Therefore, it is necessary to use drugs carefully, control administration time strictly, and take preventive measures before treatment to reduce its incidence of adverse reactions.


Keywords


Antitumor drugs; Paclitaxel; Adverse reactions; Clinical rational drug use

Full Text:

PDF

References


Deng Yin, Yang Jian. Journal of Pharmacoepide miology,2019,28(05):302-307+350. Analysis of the factors related to the use of paclitaxel injection and adverse reactions in a hospital.

Zhai Hongfa. Journal of Clinical Medicine,2017,4(76):15018+15020. (in Chinese with English abstract)

Zhao Lijie, Wu Hongjie. Int J Infect Dis,2018,16(09):140-141. (in Chinese with English abstract)

Song Yanli, Zhou Dongxian. The application of area administration of docetaxel under concentration time curve in breast cancer patients [J]. Chinese Journal of Breast Diseases,2017,11(03):179-181.

Zhou Y. Analysis of adverse reactions and clinical use of anti-tumor drug paclitaxel [J]. China Modern Drug Application,2017,11(09):138-139.

Li Q Y. Analysis of 103 cases of adverse reactions caused by antitumor drugs from 2008 to 2013 [J]. Evaluation and Analysis of Hospital Drug Use in China,2015,15(01):123-126.

Li Chunyan, Wang Yuzhen. Anti - tumor drug paclitaxel adverse reactions and clinical evaluation of clinical use [J]. Chinese Journal of Cancer Prevention and Treatment,2019,26(S1):151+153.

Yang Zhimin. Standardization of drug label and risk control: A case study of novel anti-tumor drugs [J]. China Food and Drug Administration,2019(11):40-47.

Xu K. Effects of different doses of tegafur on metabolism and adverse reactions in tumor patients [J]. Oncology,2019,32(05):393-396.

Xiong Daiqin, Mai Wu Li Dan, Halimulati, Yu Wenxiao, et al. Evaluation and analysis of adverse reaction information of antitumor drugs [J]. Chinese Journal of Hospital Pharmacy,2018,38(04):407-411.

Pan Wen, Li Yu, Huang Tianwen, et al. Analysis of 309 cases of adverse reactions caused by antitumor drugs in a tumor hospital [J]. China Pharmacy,2017,28(26):3646-3649.

Zhao Lijie, Wu Hongjie. Int J Infect Dis,2018,16(09):140-141. (in Chinese with English abstract)

Zhou Yan. Anti - tumor drug paclitaxel adverse reactions and clinical rational drug use analysis [J]. China Modern Drug Application,2017,11(09):13



DOI: http://dx.doi.org/10.30564/amor.v6i6.293

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Tianliang Zhao, Weinian Kang

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.